AntriaBio, Inc. (ANTB.OB) is another still-developing player in the sector of diabetes treatment that has recently pulled back and could be worth a look to both short- and long-term investors. This company is bringing to human trials over the near term a once-a-week basal insulin shot (AB101) that would look to replace the once-daily current standard of care. The noted benefits to a patient's quality of life that this product could have to those currently needing a shot a day is obvious, and AntriaBio shares have the potential to move in-line with catalysts as they develop during the coming quarters - especially in light of the recent pullback. After hitting highs of over two roughly a month ago, the share price has trickled lower on light volume, an indication that those who are already in are holding, while others looking to get in may do so when the see the share price settle. Given the relatively light volume, however, this one could still be trading below the radar - but that could change as progress is made this year in the clinical development of AB101.
Human trials in Russia are slated to begin over the near term and once data starts rolling in from those trials, then AntriaBio plans to use that data - assuming its positive - to search for potential partners, whether they be regional or international, according to a recent presentation (pdf). Diabetes is growing at a very rapid pace worldwide, as discussed in the SanuWave write-up, so AntriaBio could be positioning to enter a very lucrative market and could attract the swift interest of partners or potential acquirers if human trials move forward with success.
In addition to the above-mentioned catalyst events, FDA milestones could be forthcoming, as well, as the company has stated plans to proceed with the IND process in the U.S. while simultaneously conducting trials overseas. Emphasis has been put on the overseas trials first, however, due to significant costs benefits of conducting trials elsewhere, while patient recruitment is often easier, too. Once some human data is established, then it makes the FDA process at home a little bit easier. The path to approval should also be estimated as quicker than the standard drug approval process, due to the established nature of basal insulin, meaning developments could unfold quickly once trials are started.
Standard risks apply for developmental companies in the sector, but the recent price pullback, pending catalysts and overall potential of AB101 in the commercial market - should it make it that far - makes AntriaBio's recent trading action worth watching.
http://seekingalpha.com/article/1298501-weekly-stock-watch-week-of-march-25?source=yahoo
Recent RZLT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 09:14:46 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/19/2024 08:23:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 08:09:55 PM
- Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 09/19/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 11:30:26 AM
- FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Rezolute to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 08/27/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/15/2024 04:15:11 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/10/2024 01:47:17 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/05/2024 09:00:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:30:33 AM
- Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism • GlobeNewswire Inc. • 08/05/2024 11:30:00 AM
- Rezolute to Participate in the BTIG Virtual Biotechnology Conference • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds • GlobeNewswire Inc. • 06/24/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:51:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/14/2024 08:49:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:51:20 PM
- Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/14/2024 03:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/13/2024 09:25:55 PM
- Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/13/2024 08:01:00 PM
- Rezolute to Participate in the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 06:56:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 06:37:52 PM
- Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) • GlobeNewswire Inc. • 05/21/2024 08:05:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM